AC-101 is under clinical development by Accro Bioscience Suzhou and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase I drugs for Inflammatory Bowel Disease have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AC-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AC-101 overview
AC-101 is under development for the treatment of inflammation and inflammatory bowel disease (IBD) including ulcerative colitis. It is administered through oral route.
Accro Bioscience Suzhou overview
Accro Bioscience Suzhou (Accro), a subsidiary of Accro Hongkong Bioscience Co Ltd, is a biotechnology company. It focuses on the discovery and development of innovative drugs targeting inflammation, autoimmune diseases, and cancer. Its pipeline products include AC-003, AC-101, AC-201, AC-203, and AC-301. Accropeutics serves the healthcare industry, providing therapeutic solutions for inflammatory and autoimmune diseases. It develops drugs for inflammatory, autoimmune and oncology diseases. The company operates in the US, China, Japan, and Korea. Accropeutics is headquartered in Suzhou, Jiangsu, China.
For a complete picture of AC-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
